Alk Positive Non Small Cell Lung Cancer Therapeutics
1. Ensacove patent expiration
Treatment: Treatment of adult patients with anaplastic lymphoma kinase (alk)-positive locally advanced or metastatic non-small cell lung cancer (nsclc) who have not previously received an alk-inhibitor
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10899744 | XCOVERY | Crystalline form of compound suppressing protein kinase activity, and application thereof |
Jun, 2037
(11 years from now) | |
| US9296724 | XCOVERY | Substituted pyridazinecarboxamides as kinase inhibitors |
Jun, 2029
(3 years from now) | |
| US9126947 | XCOVERY | Substituted pyridazine carboxamide compounds |
Nov, 2031
(5 years from now) | |
| US8551995 | XCOVERY | Kinase inhibitor compounds |
Feb, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 18, 2029 |
Drugs and Companies using ENSARTINIB HYDROCHLORIDE ingredient
NCE-1 date: 18 December, 2028
Market Authorisation Date: 18 December, 2024
Dosage: CAPSULE
More Information on Dosage
ENSACOVE family patents
